Phase 2 Trial

Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients
EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo

Phase 2 Trial Recent News

Windtree Reveals Encouraging Data From Istaroxime Study In Early Cardiogenic Shock
Windtree Therapeutics Inc (NASDAQ: WINT) has announced positive primary results with istaroxime in rapidly raising systolic blood pressure. Istaroxime is a first-in-class dual mechanism therapy designed to improve systolic and diastolic cardiac function. 
Why Acadia Pharma Shares Are Falling Today
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 
Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) 
EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial
Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial. 
AbbVie Releases New Data From Mid-Stage Navitoclax Combo Trial In Bone Marrow Cancer
AbbVie Inc (NYSE: ABBV) has 
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
IO Biotech Inc (NASDAQ: IOBT) 
IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti Tumor Activity
IMV Inc (NASDAQ: IMV) announced 
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a 
Read Why Imara Shares Are Falling Today
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
BridgeBio Pharma Inc (NASDAQ: BBIO) 
NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped
Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in the I-SPY COVID Trial of 
Portage Biotech Shares Encouraging Preliminary Safety Data From Lead iNKT Agonists Program In Cancer Patients
Portage Biotech Inc (NASDAQ: PRTG) has updated its clinical development programs and announced its development goals for 2022, and it continues to work toward multiple clinical readouts in 2022.
Why Are Immutep Shares Trading Higher?
Immutep Limited (NASDAQ: IMMP) has 
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have 
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne 
GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved